FormulaFolio Investments LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,227 shares of the company’s stock after selling 482 shares during the period. FormulaFolio Investments LLC’s holdings in Novo Nordisk A/S were worth $221,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Fisher Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 2.9% in the fourth quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock valued at $654,329,000 after buying an additional 405,531 shares in the last quarter. Folketrygdfondet lifted its stake in shares of Novo Nordisk A/S by 0.7% in the fourth quarter. Folketrygdfondet now owns 5,732,591 shares of the company’s stock valued at $264,100,000 after buying an additional 38,642 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Novo Nordisk A/S by 6.8% in the fourth quarter. Northern Trust Corp now owns 2,319,391 shares of the company’s stock valued at $106,855,000 after buying an additional 148,443 shares in the last quarter. Boston Partners lifted its stake in shares of Novo Nordisk A/S by 4.0% in the first quarter. Boston Partners now owns 2,257,710 shares of the company’s stock valued at $118,101,000 after buying an additional 87,878 shares in the last quarter. Finally, Saratoga Research & Investment Management lifted its stake in shares of Novo Nordisk A/S by 5.1% in the first quarter. Saratoga Research & Investment Management now owns 1,510,346 shares of the company’s stock valued at $79,006,000 after buying an additional 73,054 shares in the last quarter. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

NVO opened at $48.40 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.66 and a current ratio of 0.96. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $52.83. The stock has a market cap of $115.04 billion, a P/E ratio of 19.21, a PEG ratio of 2.09 and a beta of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. The company had revenue of $4.46 billion for the quarter, compared to analyst estimates of $4.35 billion. Equities research analysts predict that Novo Nordisk A/S will post 2.46 EPS for the current fiscal year.

A number of research analysts have weighed in on the stock. Pareto Securities lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Credit Suisse Group raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. Barclays reissued a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 5th. Finally, Handelsbanken lowered shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price target on the stock. in a research report on Monday, February 4th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the stock. Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $52.31.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/formulafolio-investments-llc-sells-482-shares-of-novo-nordisk-a-s-nvo/3019472.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: Investing strategies using the yield curve

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.